Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

BioXcel Therapeutics (BTAI) Return on Sales (2022 - 2025)

BioXcel Therapeutics has reported Return on Sales over the past 4 years, most recently at 54.25% for Q4 2025.

  • Quarterly results put Return on Sales at 54.25% for Q4 2025, down 1490.0% from a year ago — trailing twelve months through Dec 2025 was 101.51% (down 6619.0% YoY), and the annual figure for FY2025 was 100.82%, down 6562.0%.
  • Return on Sales for Q4 2025 was 54.25% at BioXcel Therapeutics, up from 187.4% in the prior quarter.
  • Over the last five years, Return on Sales for BTAI hit a ceiling of 4496.0% in Q1 2022 and a floor of 305.6% in Q3 2022.
  • Median Return on Sales over the past 4 years was 83.22% (2024), compared with a mean of 171.24%.
  • Biggest five-year swings in Return on Sales: crashed -474948bps in 2023 and later surged 20739bps in 2024.
  • BioXcel Therapeutics' Return on Sales stood at 224.66% in 2022, then soared by 75bps to 55.83% in 2023, then rose by 30bps to 39.35% in 2024, then tumbled by -38bps to 54.25% in 2025.
  • The last three reported values for Return on Sales were 54.25% (Q4 2025), 187.4% (Q3 2025), and 162.09% (Q2 2025) per Business Quant data.